These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 17470690)
1. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Bennett CL; Calhoun EA Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690 [TBL] [Abstract][Full Text] [Related]
2. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024 [TBL] [Abstract][Full Text] [Related]
3. Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Yelin E; Cisternas MG; Pasta DJ; Trupin L; Murphy L; Helmick CG Arthritis Rheum; 2004 Jul; 50(7):2317-26. PubMed ID: 15248233 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Calhoun EA; Chang CH; Welshman EE; Fishman DA; Lurain JR; Bennett CL Oncologist; 2001; 6(5):441-5. PubMed ID: 11675522 [TBL] [Abstract][Full Text] [Related]
5. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection. Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970 [TBL] [Abstract][Full Text] [Related]
7. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691 [TBL] [Abstract][Full Text] [Related]
8. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. Chang S; Long SR; Kutikova L; Bowman L; Finley D; Crown WH; Bennett CL J Clin Oncol; 2004 Sep; 22(17):3524-30. PubMed ID: 15337801 [TBL] [Abstract][Full Text] [Related]
9. The economic burden of prostate cancer, California, 1998. Max W; Rice DP; Sung HY; Michel M; Breuer W; Zhang X Cancer; 2002 Jun; 94(11):2906-13. PubMed ID: 12115378 [TBL] [Abstract][Full Text] [Related]
10. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883 [TBL] [Abstract][Full Text] [Related]
11. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J; Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781 [TBL] [Abstract][Full Text] [Related]
12. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim. Annemans L; Van Overbeke N; Standaert B; Van Belle S J Nurs Manag; 2005 May; 13(3):265-74. PubMed ID: 15819840 [TBL] [Abstract][Full Text] [Related]
13. Economic costs of diabetes in the U.S. In 2007. American Diabetes Association Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683 [TBL] [Abstract][Full Text] [Related]
15. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Kuderer NM; Dale DC; Crawford J; Cosler LE; Lyman GH Cancer; 2006 May; 106(10):2258-66. PubMed ID: 16575919 [TBL] [Abstract][Full Text] [Related]
16. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662 [TBL] [Abstract][Full Text] [Related]
17. The economic burden of smoking in California. Max W; Rice DP; Sung HY; Zhang X; Miller L Tob Control; 2004 Sep; 13(3):264-7. PubMed ID: 15333882 [TBL] [Abstract][Full Text] [Related]
18. Direct and indirect costs of asthma in Canada, 1990. Krahn MD; Berka C; Langlois P; Detsky AS CMAJ; 1996 Mar; 154(6):821-31. PubMed ID: 8634960 [TBL] [Abstract][Full Text] [Related]
19. Functional disability predicts total costs in patients with ankylosing spondylitis. Ward MM Arthritis Rheum; 2002 Jan; 46(1):223-31. PubMed ID: 11817595 [TBL] [Abstract][Full Text] [Related]
20. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Delong LK; Culler SD; Saini SS; Beck LA; Chen SC Arch Dermatol; 2008 Jan; 144(1):35-9. PubMed ID: 18209166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]